Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2021 Earnings Conference Call August 5, 2021 8:30 AM ET Company Participants Joe Rayne - Argot Partners Richard Paulson - President & Chief Executive Officer Sohanya Cheng - Senior Vice President-Sales & Commercial Operations Jatin Shah - Chief Medical Officer Mike Mason - Chief Financial Officer Conference Call Participants Brian Abrams - RBC Capital Markets Peter Lawson - Barclays David Lebowitz - Morgan Stanley Eric Joseph - JPMorgan Jonathan Chang - SVB Leer ...

1 ©2021 KARYOPHARM THERAPEUTICS INC. August 5, 2021 Business Highlights & Second Quarter 2021 Financial Results On Today's Call • Welcome Joseph Rayne, Argot Partners • Overview Richard Paulson, President and Chief Executive Officer • Commercial Highlights Sohanya Cheng, SVP, Sales and Commercial Operations • Clinical Pipeline Updates Jatin Shah, MD, Chief Medical Officer • Financial Summary and Guidance Michael Mason, Chief Financial Officer • Closing Remarks Richard Paulson, President and Chief Executive ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) (State or other jur ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2021 Results Earnings Conference Call May 3, 2021 8:30 AM ET Company Participants Ian Karp - Senior Vice President, Investor and Public Relations Richard Paulson - President and Chief Executive Officer Michael Kauffman - Co-Founder, Senior Clinical Advisor and Board Member Michael Mason - Chief Financial Officer John Demaree - Chief Commercial Officer Stephen Mitchener - Chief Business Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Mau ...

1 ©2021 KARYOPHARM THERAPEUTICS INC. Investor Conference Call: First Quarter 2021 Financial Results and Business Update May 3, 2021 On Today's Call Prepared Remarks • Michael G. Kauffman, MD, PhD, Co-Founder, Senior Clinical Advisor and Board Member • Mike Mason, MBA, Chief Financial Officer • Richard Paulson, MBA, President and Chief Executive Officer Joining for Q&A Session • John Demaree, MBA, Chief Commercial Officer • Sharon Shacham, PhD, MBA, Chief Scientific Officer • Stephen Mitchener, PharmD, Chief ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 KARYOPHARM THERAPEUTICS INC. Securities registered pursuant to Section 12(g) of the Act: None Indicate by chec ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. Indicate by check mark whether the registrant has submitted electronically every Interactive ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-3931704 (State or other jurisdiction of incorporation or organization) 85 Wells Avenue, 2nd Floor Newton, MA 02459 (Address of principal executive offices) (Zip Code) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E ...

Table of Contents (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION (I.R.S. Employer Identification No.) 85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459 (Address of princ ...